WASHINGTON (AP) — The Food and Drug Administration (FDA) has revised its emergency use authorizations for updated COVID-19 vaccines, narrowing eligibility to seniors, immunocompromised individuals, and those with high-risk health conditions. The decision, announced on August 27, also revokes authorization for Pfizer’s vaccine in healthy children under the age of 5, leaving only limited access through Moderna for young children with serious medical vulnerabilities.
Key Changes to Vaccine Authorization
The FDA approved reformulated vaccines from Pfizer, Moderna, and Novavax aimed at offering protection against the most recent COVID-19 variants. However, the agency restricted widespread use, citing what it described as “shifting public health priorities” and declining hospitalization rates among the general population.
“Updated vaccines remain an essential tool for protecting older adults and those with underlying conditions,” an FDA spokesperson said in a statement. “Our revisions reflect the current evidence on risk and benefit.”
The decision effectively ends Pfizer’s emergency use authorization for children under 5, a group that had previously been eligible under limited circumstances. Moderna’s vaccine remains authorized, but only for young children with serious health complications. The full authorization letters are available on the FDA’s website.
Reaction From Pediatric and Medical Groups
The move sparked immediate backlash from medical experts and child health advocates. The American Academy of Pediatrics (AAP) strongly objected, warning that excluding healthy children under 5 from authorized access could leave them vulnerable.
“COVID-19 continues to pose risks to children, even if those risks are lower than for adults,” the AAP said in a statement. “Removing authorization for healthy young children creates unnecessary barriers for families and undermines confidence in pediatric care.”
Dr. Sean O’Leary, chair of the AAP’s Committee on Infectious Diseases, told reporters the decision “sends the wrong message” about the importance of pediatric protection against COVID-19.
Cost Concerns for Families
Another major concern centers on insurance coverage. Under the Affordable Care Act, insurers are required to cover CDC-recommended vaccines without out-of-pocket costs. However, vaccines outside of FDA or CDC authorization may not be covered.
Families seeking vaccines for children now excluded from eligibility could face costs ranging from $140 to $200 per dose, according to estimates reported by the San Francisco Chronicle and ABC News. For families with multiple children, these costs could be significant.
The Centers for Medicare & Medicaid Services (CMS) has not yet clarified how insurance companies should handle off-label COVID-19 vaccinations. More guidance is expected in the coming weeks.
Public Health Implications
While COVID-19 cases and hospitalizations remain well below pandemic peaks, experts caution that the virus continues to circulate and could surge again during the winter months. Restricting vaccine access may leave some populations less protected, particularly families with children in daycare or preschool settings.
Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, said the decision could “widen disparities in protection,” particularly among communities with limited healthcare access. “This is not the moment to roll back childhood vaccination,” Hotez said.
The Centers for Disease Control and Prevention (CDC) is expected to issue updated vaccination recommendations later this week, which will determine whether insurers and state programs adjust coverage policies.
Looking Ahead
The FDA’s narrowing of authorization highlights the shifting landscape of COVID-19 policy as the U.S. moves further away from the height of the pandemic. Still, the decision underscores an ongoing debate between regulators, pediatricians, and public health advocates over how to balance risk, cost, and access in a post-emergency era.
For now, parents of young children not deemed high-risk may face tough choices between paying out of pocket or forgoing vaccination altogether. As winter approaches, the debate over who gets vaccinated—and who pays for it—is expected to intensify.